Cited by 143Amyotrophic Lateral Sclerosis ResearchGenetic Neurodegenerative DiseasesAlzheimer's disease research and treatments

Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease

Lindquist, SG, Duno, M, Batbayli, M, Puschmann, A, Braendgaard, H, Mardosiene, S, Svenstrup, K, Pinborg, LH +6 more·2013·Clinical Genetics

Abstract

Recently, a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 was reported as the cause of chromosome 9p21‐linked frontotemporal dementia‐amyotrophic lateral sclerosis (FTD‐ALS). We here report the prevalence of the expansion in a hospital‐based cohort and associated clinical features indicating a wider clinical spectrum of C9ORF72 disease than previously described. We studied 280 patients previously screened for mutations in genes involved in early onset autosomal dominant inherited dementia disorders. A repeat‐primed polymerase chain reaction amplification assay was used to identify pathogenic GGGGCC expansions. As a potential modifier, confirmed cases were further investigated for abnormal CAG expansions in ATXN2. A pathogenic GGGGCC expansion was identified in a total of 14 probands. Three of these presented with atypical clinical features and were previously diagnosed with clinical olivopontocerebellar degeneration (OPCD), atypical Parkinsonian syndrome (APS) and a corticobasal syndrome (CBS). Further, the pathogenic expansion was identified in six FTD patients, four patients with FTD‐ALS and one ALS patient. All confirmed cases had normal ATXN2 repeat sizes. Our study widens the clinical spectrum of C9ORF72 related disease and confirms the hexanucleotide expansion as a prevalent cause of FTD‐ALS disorders. There was no indication of a modifying effect of the ATXN2 gene.

Integrity signals

Registry

Crossref · 10.1111/j.1399-0004.2012.01903.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • C9orf72 expansion mutations are associated with ALS/FTLD and also with symptoms reminiscent of Parkinson disease, Alzheimer disease, Huntington disease, and corticobasal syndrome.

    “For instance, C9orf72 expansion mutations are associated not only with ALS/FTLD, but also with symptoms reminiscent of Parkinson disease, Alzheimer disease, Huntington disease, and corticobasal syndrome, reinforcing the imperfect connection between clinical and molecular phenotypes and emphasizing the need for molecular diagnostics [155–164].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lindquist, S., Duno, M., Batbayli, M., Puschmann, A., Braendgaard, H., Mardosiene, S., Svenstrup, K., Pinborg, L., Vestergaard, K., Hjermind, L., Stokholm, J., Andersen, B., Johannsen, P., & Nielsen, J.
Affiliations
  • Department of Clinical Genetics 4062, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark
  • Copenhagen University Hospital (DK)
  • Skåne University Hospital (SE)
  • Department of Neurology Aarhus Sygehus, Aarhus University Hospital Aarhus Denmark
  • Bispebjerg Hospital (DK)
  • University of Copenhagen (DK)
  • Neurobiology Research Unit, Department of Neurology Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark
  • Aalborg University Hospital (DK)
Venue
Clinical Genetics
Publisher
Wiley
Published
2013-03
Volume
83
Issue
3
Pages
279-283
ISSN
  • 0009-9163 (ISSN-L)
  • 1399-0004
OpenAlex
W1763842383
Cited by
143
References
15
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 13 · 2020: 4 · 2019: 9 · 2018: 6 · 2017: 9 · 2016: 15 · 2015: 18 · 2014: 18 · 2013: 23 · 2012: 6
FWCI
13.54
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Genetics (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Funders
Novo Nordisk Fonden (NNF11OC1014514)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
C9orf72, GGGGCC repeat expansion, hexanucleotide repeat expansion, frontotemporal dementia, amyotrophic lateral sclerosis, corticobasal syndrome, ataxia, olivopontocerebellar degeneration, atypical parkinsonism, ATXN2, CAG repeat expansion, clinical spectrum, chromosome 9p21
MeSH terms
C9orf72 Protein, Adult, Aged, Amyotrophic Lateral Sclerosis, Ataxia, Base Sequence, Family Health, Female, Genetic Testing, Humans, Male, Middle Aged, Proteins, Syndrome, Cohort Studies, Genetic Predisposition to Disease, DNA Repeat Expansion, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review